Adverum Biotechnologies to Participate in Upcoming Conferences

MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company’s participation in several upcoming conferences:

Event: Chardan’s In Vivo Gene Therapy and Gene Editing SummitPanel Title: Gene Therapy and Gene Editing to the RetinaPanel Participant: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum BiotechnologiesDate: Monday, March 18, 2019Time: 5:05 – 6:05 pm ETLocation: Miami, Florida

Event: Retina World Congress UnpluggedPanel Title: Cell and Gene Therapy Panel Moderator: Pravin Dugel, M.D., managing partner of Retinal Consultants of Arizona and clinical professor at the Department of Ophthalmology at the Keck School of Medicine, University of Southern CaliforniaPanel Participant: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum BiotechnologiesDate: Thursday, March 21, 2019Time: 10:07 – 10:34 am ETLocation: Fort Lauderdale, FL

Event:  2019 Cell & Gene Meeting on the MediterraneanPresentation by: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum BiotechnologiesDate:   April 22 – 24, 2019Time:   1:35 pm CETLocation: Hotel Arts Barcelona, Marina 19-21, 08005 Barcelona, SpainWebcast: http://www.meetingonthemed.com/webcast

About Adverum Biotechnologies, Inc.Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. As a leader in ophthalmic gene therapy, Adverum has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.

Investor and Media Inquiries:
Amy Figueroa, CFA
Investor Relations Consultant
[email protected]
650-823-2704

Source: Adverum Biotechnologies, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Chardan Assumes Rocket Pharmaceuticals (RCKT) at Buy
• Blue Star Announces Non-Brokered Private Placement and Proposed Debt Settlement
• Crypto News: AlphaPepe Announces $2.57M Raised in Presale as XRP Price Prediction Eyes $5